Therefore, the PSMA-T4 has been developed considering the most suitable linkers set for Glu-urea-Lys to connect HYNIC moiety, which could lead to an improvement in the pharmacokinetics of the 99mTc-PSMA compound by increasing tumor accumulation and reducing kidney accumulation. Here, CD4 is linked to neoplasm.